Evidence map›Paper›PMID 24959826›Full record

ArticlePloS one2014

Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.

Inés Gómez-Seguí, Dolors Sánchez-Izquierdo, Eva Barragán, Esperanza Such, Irene Luna, María López-Pavía, Mariam Ibáñez, Eva Villamón, Carmen Alonso, Iván Martín and 9 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Inés Gómez-SeguíHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Dolors Sánchez-IzquierdoArray's Unit. Instituto Investigación Sanitaria Fundación La Fe, Valencia, Spain.
Eva BarragánLaboratory of Molecular Biology, Department of Clinical Chemistry, University Hospital La Fe, Valencia, Spain.
Esperanza SuchHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Irene LunaHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
María López-PavíaHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Mariam IbáñezHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Eva VillamónHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Carmen AlonsoHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Iván MartínHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Marta LlopLaboratory of Molecular Biology, Department of Clinical Chemistry, University Hospital La Fe, Valencia, Spain.
Sandra DolzLaboratory of Molecular Biology, Department of Clinical Chemistry, University Hospital La Fe, Valencia, Spain.
Oscar FusterLaboratory of Molecular Biology, Department of Clinical Chemistry, University Hospital La Fe, Valencia, Spain.
Pau MontesinosHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Carolina CañigralHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Blanca BoludaHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Claudia SalazarHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Jose CerveraHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Genetics Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Miguel A SanzHematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Department of Medicine, University of Valencia, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (6%) the most frequent copy-number abnormalities (CNA). Four patients (8%) showed CNAs adjacent to the breakpoints of the translocation. We compared our results with other APL series and found that, except for dup(8q24) and del(7q33-qter), ACA were infrequent (≤3%) but most of them recurrent (70%). Interestingly, having CNA or FLT3 mutation were mutually exclusive events. Neither the number of CNA, nor any specific CNA was associated significantly with prognosis. This study has delineated recurrent abnormalities in addition to t(15;17) that may act as secondary events and could explain leukemogenesis in up to 40% of APL cases with no ACA by conventional cytogenetics.

Indexed as

KaryotypingPolymorphism, Single NucleotideAdolescentAdultAgedChromosome AberrationsChromosomes, Human, Pair 15Chromosomes, Human, Pair 17FemaleHumansLeukemia, Promyelocytic, AcuteLoss of HeterozygosityMaleMiddle AgedOncogene Proteins, FusionPrognosisOncogene Proteins, Fusion

Identifiers

PMID24959826
PMCPMC4069034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.